Trial Profile

PrEPared to Choose (PtC): an Implementation Study of the Delivery of Cabotegravir Long-acting Injectable Pre-exposure Prophylaxis (PrEP) As an HIV Prevention Product Option Within a PrEP Choice Context in a Real World Setting in Cape Town.

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabotegravir (Primary) ; Dapivirine (Primary) ; Emtricitabine/tenofovir (Primary)
Indications HIV infections
Focus Therapeutic Use
Acronyms PrEPared to Choose (PtC)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com